Experiencing daytime sleepiness is something that is usually perceived as a minor inconvenience, but for older adults, it could be an early warning sign of Dementia. This neurodegenerative disease leads to the progressive decline of brain cells. This eventually

affects memory, cognition, and personality, making everyday tasks more difficult. As one of the fastest-growing neurological disorders across the world, dementia poses a significant health threat to ageing populations.

Is Dementia Linked To Poor Sleep?

For this study, researchers followed 445 older adults (average age 76) over three years, aiming to determine whether poor sleep could increase the risk of mild cognitive impairment (MCI), which often leads to dementia. At the start, none of the participants had MCI, but by the end of the study, 36 individuals had developed the condition.

The researchers discovered that participants with poor sleep were more likely to develop MCI compared to those who slept well. However, when depression symptoms were taken into account, the link between poor sleep and MCI became less pronounced, suggesting that while sleep issues are a concern, mental health also plays a key role in dementia risk.

To assess sleep quality, the Pittsburgh Sleep Quality Index (PSQI) was used, evaluating factors such as sleep duration, disturbances, and daytime alertness. Among these, "daytime dysfunction"—defined as excessive sleepiness and low energy during the day—was most strongly associated with an increased risk of MCI. Those experiencing daytime dysfunction were more than three times as likely to develop MCI as those who didn’t report such symptoms.

There are many types of dementia:

Dementia is not a specific disease. According to the Centers for Disease Control and Prevention (CDC), it is an overall term that describes a decline in mental ability that interferes with daily life. People with dementia often have symptoms like trouble remembering, thinking, or making everyday decisions. These symptoms tend to get worse over time.

Alzheimer’s disease is the most common type of dementia, and it mostly affects the elderly. Each form of dementia has a different cause. Though dementia mostly affects older adults, it is not a part of normal ageing. An estimated 6.7 million older adults have Alzheimer's disease in the United States. That number is expected to double by 2060, as per data from the CDC.

In 2022, 3.8% of men and 4.2% women in US were diagnosed with dementia. The percentage of people increase with age from 1.7% for those aged 65-74 to 13.1% for those aged 85 and older. Alzheimer's accounts for 60 to 80% of all dementia cases and it is most prevalent in California, Florida, and Texas, as these states have the highest number of people.

Cancer recurrence remains one of the biggest challenges in cancer treatment. Dormant tumour cells are capable of surviving treatment and therapy and can reactivate months or even years later.

Now, researchers say that a new generation of experimental drugs designed to target these dormant cancer cells could offer a promising strategy to prevent the disease from recurring.

The findings come as scientists have been increasingly focusing on tumour dormancy, a state in which cancer cells stop actively multiplying but remain hidden in the body. They become resistant to chemotherapy and other conventional cancer treatments.

The research suggests that targeting the biological pathways controlling dormancy may help stop these cells from getting reactivated and forming new tumours or metastases.

According to researchers, dormant cancer cells are one of the key reasons why some patients experience relapse long after completing treatment.

"Dormant tumour cells are a major driver of cancer recurrence and metastasis," the researchers noted, stating that therapies aimed at controlling or eliminating these cells could change how cancer is treated and managed in the future.

About The Experimental Drugs

Also read: Bone Marrow Transplant: The Quiet Revolution Transforming India's Fight Against Blood Cancers

Unlike traditional cancer treatments that mainly attack rapidly dividing cells, these new experimental drugs target the molecular signals that allow dormant cancer cells to survive and go unnoticed in the body.

Researchers are investigating several approaches, including blocking pathways that trigger dormant cells to become active again, disrupting the cells' survival mechanisms, and making them more vulnerable to conventional cancer therapies.

Some experimental treatments are also being tested alongside immunotherapy to improve the body's ability to detect and destroy these hidden cells on time.

Scientists say this approach could be especially important for cancers known to recur years after treatment, including breast, lung and certain gastrointestinal cancers.

Why Do Some Cancers Return?

Also read: NHS Breast Cancer Screening Misses 95% Of High-Risk Young Women In UK: Why Personalized Care Could Be Key

Cancer recurrence can happen when a small number of cells survive surgery, chemotherapy or radiation. These cells may remain inactive for long periods of time before starting to grow again, eventually leading to a relapse or metastatic diseas.

Researchers believe that the environment of the tumour, immune responses, inflammation and changes in cellular structure and metabolism all play a role in determining whether dormant cancer cells remain inactive or become aggressive again.

While the findings encourage advanced pathways for cancer treatments, experts caution that most drugs that target tumour dormancy are still in the experimental or early clinical trial stage.

Rather than only treating visible tumours, future therapies may also focus on preventing hidden cancer cells from ever becoming active again, potentially reducing the risk of relapse years after successful treatment.

More studies are needed to determine whether they can really reduce cancer recurrence and improve long-term survival in patients.

Viagra May Prevent Cancer From Spreading

The promising research comes after a new study found that Viagra, best known as a treatment for erectile dysfunction, may also help stop cancer from spreading.

Researchers from the Weizmann Institute of Science in Israel found that sildenafil, the active ingredient in Viagra, may enhance a newly identified cholesterol-regulating mechanism that could be used to curb cancer metastasis.

The study, published in Cancer Research, showed that sildenafil limits cancer cells' ability to use cholesterol, an essential component of cell membranes.

Cholesterol is especially important for cancer cells that break away from the primary tumor, travel through the body, and invade distant organs. When their access to cholesterol is reduced, these cells have greater difficulty forming metastases.

A common amino acid found in protein-rich foods, which is also available as an dietary supplement, may have surprising potential for strengthening the body's immune response against cancer and viral infections, according to a new study.

Published in the journal Cell, researchers from Rockefeller University found that arginine plays a key role in helping immune cells detect and attack abnormal cells.

Their findings suggest that restoring arginine levels could improve the effectiveness of the body's natural defences and may one day strengthen cancer or antiviral treatments.

"Our work reveals how a lack of arginine interferes with the immune system, and suggests that upping arginine intake could prove beneficial," said Qiushuang Wu, the study's first author and a postdoctoral researcher at Rockefeller University. "Perhaps that means it could be used in combination with other therapies to treat both cancer and viral infections."

What Are The Findings?

The team investigated how low arginine levels affect gene expression in models of colon cancer, influenza and SARS-CoV-2 infection.

They found that arginine deficiency disrupted the production of major histocompatibility complex class I (MHC-I) proteins, molecules that help cells, allowing the immune system to detect and fight virus-infected or cancerous cells in the body.

The researchers discovered that when arginine was low, ribosomes, the cellular machinery responsible for making proteins, stalled while producing MHC-I proteins. As a result, infected or abnormal cells became harder for the immune system to identify.

However, after giving a moderate amount of arginine, roughly equivalent to a couple of over-the-counter tablets, restored the production of these stalled proteins.

Also read: Bone Marrow Transplant: The Quiet Revolution Transforming India's Fight Against Blood Cancers

Many cancers and viral infections are known to alter amino acid levels in the body. The new findings suggest that these changes may weaken immunity in an unexpected way by limiting the production of proteins essential for a stronger immune response.

Senior author Sohail Tavazoie, head of Rockefeller University's Laboratory of Systems Cancer Biology, believes the discovery could become an asset for future clinical research, especially in cancer treatment studies.

"Arginine supplementation could be readily tested in patients receiving immunotherapies or given to high-risk populations exposed to viral pathogens," Tavazoie said. "Considering that arginine is inexpensive and readily available, we hope that therapeutic and preventative studies could be undertaken soon."

What Is Arginine?

Arginine is an essential amino acid, meaning the body usually produces. Additional amounts of of arginine may be needed during illness, injury or periods of physiological distress to the body.

It is naturally found in foods such as meat, poultry, fish, dairy products, nuts, seeds and legumes. It is also sold as a dietary supplement. It also serves as a building block for nitric oxide, a molecule involved in blood flow and immune function.

While the findings are promising, the researchers emphasise that the study does not prove that taking arginine supplements can prevent or treat cancer or viral infections in people.

Reliable human clinical trials are still needed to determine whether the supplementation is safe, effective and beneficial.

On August 5, 2026, New York's Medical Aid in Dying (MAID) Act comes into effect which will allow eligible patients with a terminal illness to choose to peacefully end their lives. The end-of-life healthcare will enable patients to have access to end-of-life medications that they could self-administer.

The law marks a significant step in end-of-life healthcare, placing New York among the growing number of U.S. states offering medically assisted dying under strict legal safeguards.

About The Law

The law is intended for adults who are

• New York residents
• 18 years and older
• Diagnosed with a terminal illness with a life expectancy of six months or less
• Mentally capable of making healthcare decisions
• Physically able to self-administer the medication
• Receive approval from two physicians
• Undergo a mandatory mental health evaluation by a psychiatrist

The end-of-life right is not available for people with chronic illnesses alone, advanced dementia, or individuals who cannot make informed medical decisions.

Health experts emphasize that medical aid in dying is not the same as euthanasia. Under New York's law, the patient, not the physician, must voluntarily take the prescribed medication.

Doctors evaluate eligibility, discuss alternative care options such as hospice and palliative care, and ensure that the request is informed and free from coercion before a prescription can be issued. Multiple medical assessments are required, making the process regulated and full-proof.

Also read: Assisted Dying Bill Passed In UK: What It Means And How It Changes For End-of-Life Care Forever?

Reactions

Supporters say the legislation gives terminally ill patients greater autonomy during the final stages of life. Many advocacy groups argue that simply having the option can provide psychological comfort, even for patients who ultimately never take the medication.

Experiences from states where similar laws have existed for years suggest that a significant number of eligible patients obtain the prescription but do not use it.

They instead find reassurance in knowing that they have a choice if suffering becomes unbearable.

At the same time, the law continues to spark ethical and legal debate. Disability rights advocates and some religious organizations have voiced concerns about potential risks to vulnerable populations and the broader implications for end-of-life care.

A group of Catholic healthcare providers has already challenged the law in federal court, arguing that certain provisions requiring patient transfers conflict with their religious beliefs.

For healthcare professionals, the implementation of the MAID Act also means preparing new medical protocols, reporting requirements, and giving appropriate training to staff.

The New York State Department of Health has introduced regulations outlining eligibility criteria, documentation, and safeguards to ensure the law is implemented responsibly while protecting both patients and healthcare providers.

Also read: What Are The Dutch Guidelines Of Active Euthanasia And The Countries That Allow It

Canada Banned Assisted Dying For Mental Illness Alone

Recently, a parliamentary committee in Canada recommended that the country's assisted dying laws must continue to exclude people whose sole underlying condition is a mental illness.

When MAID was introduced in 2016 in Canada, it was available only to adults who were terminally ill. The eligibility criteria were strict.

Individuals had to be suffering from a "serious and incurable illness", be in an "advanced state of irreversible decline", experience "intolerable suffering", and have a natural death that was "reasonably foreseeable".

This legal pathway became primarily served people with terminal cancer or other severe illnesses who wanted greater control over the dying process.

However, many Canadians living with severe non-terminal conditions argued that they were excluded from the law. These included people with degenerative diseases, chronic pain, or spinal injuries who experienced significant suffering but were not nearing death. Many requested MAID but were routinely denied.